9.090USD-0.11%Mkt Cap: 586.50M USDP/E: —Last update: 2026-05-22
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (P…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap586.50M USD
Enterprise Value-19.36M USD
Revenue (TTM)89.40M USD
Gross Profit120.20M USD
Net Income (TTM)-80.80M USD
Revenue/Share1.300 USD
Last Price9.090 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees246
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.73
PEG—
EV/EBITDA0.08
EV/Revenue-0.22
P/S6.57
P/B1.52
EPS (TTM)-3.18
EPS (Forward)-3.33
52W Range
6.06036% of range14.51
52W High14.51 USD
52W Low6.060 USD
Profitability
Gross Margin134.45%
Oper. Margin-405.13%
EBITDA Margin-275.73%
Profit Margin-30.77%
ROE-18.63%
ROA-11.26%
Growth
Revenue Growth-91.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-273.80M USD
CapEx (TTM)1.90M USD
FCF Margin-223.31%
FCF Yield-34.04%
Net Debt-606.50M USD
Net Debt/EBITDA2.46
Balance Sheet
Debt/Equity0.02
Current Ratio5.44
Quick Ratio5.36
Book Value/Sh5.997 USD
Cash/Share9.530 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.2 (Buy)
Target (Mean)15.00 USD
Target Range6.000 USD – 24.00 USD
# Analysts16
Ownership
Shares Out.64.52M
Float55.97M
Insiders7.77%
Institutions83.12%
Short Interest
Short Ratio5.8d
Short % Float8.00%
Short % Out.6.85%
Shares Short4.42M
Short (prev mo.)4.51M
Technical
SMA 5010.53 (-13.7%)
SMA 20010.59 (-14.2%)
Beta1.80
S&P 52W Chg28.31%
Avg Vol (30d)884.76K
Avg Vol (10d)1.06M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—